Single User License
INR 168550
Site License
INR 337100
Corporate User License
INR 505650

Service Tax Additional

select a format
Price

Single User License
USD 2500
Site License
USD 5000
Corporate User License
USD 7500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Colorectal Cancer-Pipeline Review, H1 2015

Colorectal Cancer-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Colorectal Cancer-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Colorectal Cancer-Pipeline Review, H1 2015', provides an overview of the Colorectal Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Colorectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colorectal Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Colorectal Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Colorectal Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Colorectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Colorectal Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Colorectal Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Colorectal Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 10

Colorectal Cancer Overview 11

Therapeutics Development 12

Colorectal Cancer-Therapeutics under Development by Companies 14

Colorectal Cancer-Therapeutics under Investigation by Universities/Institutes 30

Colorectal Cancer-Pipeline Products Glance 34

Colorectal Cancer-Products under Development by Companies 38

Colorectal Cancer-Products under Investigation by Universities/Institutes 60

Colorectal Cancer-Companies Involved in Therapeutics Development 63

Colorectal Cancer-Therapeutics Assessment 241

Drug Profiles 274

Colorectal Cancer-Recent Pipeline Updates 884

Colorectal Cancer-Dormant Projects 1222

Colorectal Cancer-Discontinued Products 1244

Colorectal Cancer-Product Development Milestones 1250

Appendix 1260

List of Tables

Number of Products under Development for Colorectal Cancer, H1 2015 50

Number of Products under Development for Colorectal Cancer-Comparative Analysis, H1 2015 51

Number of Products under Development by Companies, H1 2015 53

Number of Products under Development by Companies, H1 2015 (Contd..1) 54

Number of Products under Development by Companies, H1 2015 (Contd..2) 55

Number of Products under Development by Companies, H1 2015 (Contd..3) 56

Number of Products under Development by Companies, H1 2015 (Contd..4) 57

Number of Products under Development by Companies, H1 2015 (Contd..5) 58

Number of Products under Development by Companies, H1 2015 (Contd..6) 59

Number of Products under Development by Companies, H1 2015 (Contd..7) 60

Number of Products under Development by Companies, H1 2015 (Contd..8) 61

Number of Products under Development by Companies, H1 2015 (Contd..9) 62

Number of Products under Development by Companies, H1 2015 (Contd..10) 63

Number of Products under Development by Companies, H1 2015 (Contd..11) 64

Number of Products under Development by Companies, H1 2015 (Contd..12) 65

Number of Products under Development by Companies, H1 2015 (Contd..13) 66

Number of Products under Development by Companies, H1 2015 (Contd..14) 67

Number of Products under Investigation by Universities/Institutes, H1 2015 69

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 70

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 71

Comparative Analysis by Late Stage Development, H1 2015 72

Comparative Analysis by Clinical Stage Development, H1 2015 73

Comparative Analysis by Early Stage Development, H1 2015 74

Comparative Analysis by Unknown Stage Development, H1 2015 75

Products under Development by Companies, H1 2015 76

Products under Development by Companies, H1 2015 (Contd..1) 77

Products under Development by Companies, H1 2015 (Contd..2) 78

Products under Development by Companies, H1 2015 (Contd..3) 79

Products under Development by Companies, H1 2015 (Contd..4) 80

Products under Development by Companies, H1 2015 (Contd..5) 81

Products under Development by Companies, H1 2015 (Contd..6) 82

Products under Development by Companies, H1 2015 (Contd..7) 83

Products under Development by Companies, H1 2015 (Contd..8) 84

Products under Development by Companies, H1 2015 (Contd..9) 85

Products under Development by Companies, H1 2015 (Contd..10) 86

Products under Development by Companies, H1 2015 (Contd..11) 87

Products under Development by Companies, H1 2015 (Contd..12) 88

Products under Development by Companies, H1 2015 (Contd..13) 89

Products under Development by Companies, H1 2015 (Contd..14) 90

Products under Development by Companies, H1 2015 (Contd..15) 91

Products under Development by Companies, H1 2015 (Contd..16) 92

Products under Development by Companies, H1 2015 (Contd..17) 93

Products under Development by Companies, H1 2015 (Contd..18) 94

Products under Development by Companies, H1 2015 (Contd..19) 95

Products under Development by Companies, H1 2015 (Contd..20) 96

Products under Development by Companies, H1 2015 (Contd..21) 97

Products under Investigation by Universities/Institutes, H1 2015 98

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 99

Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 100

Colorectal Cancer-Pipeline by 2cureX ApS, H1 2015 101

Colorectal Cancer-Pipeline by 3-V Biosciences, Inc., H1 2015 102

Colorectal Cancer-Pipeline by 4SC AG, H1 2015 103

Colorectal Cancer-Pipeline by AB Science, H1 2015 104

Colorectal Cancer-Pipeline by AbbVie Inc., H1 2015 105

Colorectal Cancer-Pipeline by Actinium Pharmaceuticals, Inc., H1 2015 106

Colorectal Cancer-Pipeline by Adamed Sp. z o.o., H1 2015 107

Colorectal Cancer-Pipeline by Advaxis, Inc., H1 2015 108

Colorectal Cancer-Pipeline by Advenchen Laboratories, LLC, H1 2015 109

Colorectal Cancer-Pipeline by Aeterna Zentaris Inc., H1 2015 110

Colorectal Cancer-Pipeline by Alchemia Limited, H1 2015 111

Colorectal Cancer-Pipeline by Allinky Biopharma, H1 2015 112

Colorectal Cancer-Pipeline by Amgen Inc., H1 2015 113

Colorectal Cancer-Pipeline by Angiogene Pharmaceuticals Limited, H1 2015 114

Colorectal Cancer-Pipeline by Antibe Therapeutics, Inc., H1 2015 115

Colorectal Cancer-Pipeline by Aphios Corporation, H1 2015 116

Colorectal Cancer-Pipeline by Arisaph Pharmaceuticals, Inc., H1 2015 117

Colorectal Cancer-Pipeline by ArQule, Inc., H1 2015 118

Colorectal Cancer-Pipeline by Array BioPharma Inc., H1 2015 119

Colorectal Cancer-Pipeline by Astellas Pharma Inc., H1 2015 120

Colorectal Cancer-Pipeline by Astex Pharmaceuticals, Inc., H1 2015 121

Colorectal Cancer-Pipeline by AstraZeneca Plc, H1 2015 122

Colorectal Cancer-Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 123

Colorectal Cancer-Pipeline by Basilea Pharmaceutica AG, H1 2015 124

Colorectal Cancer-Pipeline by Bavarian Nordic A/S, H1 2015 125

Colorectal Cancer-Pipeline by Bayer AG, H1 2015 126

Colorectal Cancer-Pipeline by Biocon Limited, H1 2015 127

Colorectal Cancer-Pipeline by Bionomics Limited, H1 2015 128

Colorectal Cancer-Pipeline by BioNovion B.V., H1 2015 129

Colorectal Cancer-Pipeline by Biothera, Inc., H1 2015 130

Colorectal Cancer-Pipeline by Boehringer Ingelheim GmbH, H1 2015 131

Colorectal Cancer-Pipeline by Boston Biomedical, Inc., H1 2015 132

Colorectal Cancer-Pipeline by Bristol-Myers Squibb Company, H1 2015 133

Colorectal Cancer-Pipeline by Burzynski Research Institute, Inc., H1 2015 134

Colorectal Cancer-Pipeline by cCAM Biotherapeutics Ltd., H1 2015 135

Colorectal Cancer-Pipeline by CCRP Therapeutics GmbH, H1 2015 136

Colorectal Cancer-Pipeline by Celator Pharmaceuticals, Inc., H1 2015 137

Colorectal Cancer-Pipeline by Celgene Corporation, H1 2015 138

Colorectal Cancer-Pipeline by Celldex Therapeutics, Inc., H1 2015 139

Colorectal Cancer-Pipeline by Cellectar Biosciences, Inc., H1 2015 140

Colorectal Cancer-Pipeline by Cellectis S.A., H1 2015 141

Colorectal Cancer-Pipeline by Celltrion, Inc., H1 2015 142

Colorectal Cancer-Pipeline by Cellular Biomedicine Group, Inc., H1 2015 143

Colorectal Cancer-Pipeline by Celon Pharma Sp. z o.o., H1 2015 144

Colorectal Cancer-Pipeline by Celsion Corporation, H1 2015 145

Colorectal Cancer-Pipeline by Chipscreen Biosciences Ltd, H1 2015 146

Colorectal Cancer-Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2015 147

Colorectal Cancer-Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2015 148

Colorectal Cancer-Pipeline by Critical Outcome Technologies Inc., H1 2015 149

Colorectal Cancer-Pipeline by CritiTech, Inc., H1 2015 150

Colorectal Cancer-Pipeline by CrystalGenomics, Inc., H1 2015 151

Colorectal Cancer-Pipeline by CTI BioPharma Corp., H1 2015 152

Colorectal Cancer-Pipeline by CureTech Ltd., H1 2015 153

Colorectal Cancer-Pipeline by Cytune Pharma SAS, H1 2015 154

Colorectal Cancer-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 155

Colorectal Cancer-Pipeline by DanDrit Biotech A/S, H1 2015 156

Colorectal Cancer-Pipeline by Deciphera Pharmaceuticals, LLC, H1 2015 157

Colorectal Cancer-Pipeline by Dicerna Pharmaceuticals, Inc., H1 2015 158

Colorectal Cancer-Pipeline by Digna Biotech, S.L., H1 2015 159

Colorectal Cancer-Pipeline by Eddingpharm, H1 2015 160

Colorectal Cancer-Pipeline by Eisai Co., Ltd., H1 2015 161

Colorectal Cancer-Pipeline by Eli Lilly and Company, H1 2015 162

Colorectal Cancer-Pipeline by EntreChem, S.L., H1 2015 163

Colorectal Cancer-Pipeline by Enzo Biochem, Inc., H1 2015 164

Colorectal Cancer-Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 165

Colorectal Cancer-Pipeline by Etubics Corporation, H1 2015 166

Colorectal Cancer-Pipeline by Exelixis, Inc., H1 2015 167

Colorectal Cancer-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 168

Colorectal Cancer-Pipeline by Fusion Antibodies Limited, H1 2015 169

Colorectal Cancer-Pipeline by Genentech, Inc., H1 2015 170

Colorectal Cancer-Pipeline by Genor BioPharma Co., Ltd., H1 2015 171

Colorectal Cancer-Pipeline by Gilead Sciences, Inc., H1 2015 172

Colorectal Cancer-Pipeline by GlaxoSmithKline Plc, H1 2015 173

Colorectal Cancer-Pipeline by Glycotope GmbH, H1 2015 174

Colorectal Cancer-Pipeline by Golden Biotechnology Corp., H1 2015 175

Colorectal Cancer-Pipeline by Gradalis Inc., H1 2015 176

Colorectal Cancer-Pipeline by Green Cross Corporation, H1 2015 177

Colorectal Cancer-Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 178

Colorectal Cancer-Pipeline by Helix BioPharma Corp., H1 2015 179

Colorectal Cancer-Pipeline by Hemispherx Biopharma, Inc., H1 2015 180

Colorectal Cancer-Pipeline by Hospira, Inc., H1 2015 181

Colorectal Cancer-Pipeline by Hutchison MediPharma Limited, H1 2015 182

Colorectal Cancer-Pipeline by iDD biotech SAS, H1 2015 183

Colorectal Cancer-Pipeline by Ignyta, Inc., H1 2015 184

Colorectal Cancer-Pipeline by immatics biotechnologies GmbH, H1 2015 185

Colorectal Cancer-Pipeline by Immodulon Therapeutics Ltd., H1 2015 186

Colorectal Cancer-Pipeline by ImmuneXcite, Inc., H1 2015 187

Colorectal Cancer-Pipeline by ImmunNovative Developments SL, H1 2015 188

Colorectal Cancer-Pipeline by Immunomedics, Inc., H1 2015 189

Colorectal Cancer-Pipeline by Immunovative Therapies, Ltd., H1 2015 190

Colorectal Cancer-Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015 191

Colorectal Cancer-Pipeline by Incuron, LLC, H1 2015 192

Colorectal Cancer-Pipeline by Incyte Corporation, H1 2015 193

Colorectal Cancer-Pipeline by Innovent Biologics, Inc., H1 2015 194

Colorectal Cancer-Pipeline by Interprotein Corporation, H1 2015 195

Colorectal Cancer-Pipeline by Isis Pharmaceuticals, Inc., H1 2015 196

Colorectal Cancer-Pipeline by Isofol Medical AB, H1 2015 197

Colorectal Cancer-Pipeline by ISU ABXIS Co.,Ltd., H1 2015 198

Colorectal Cancer-Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2015 199

Colorectal Cancer-Pipeline by Kadmon Corporation, LLC, H1 2015 200

Colorectal Cancer-Pipeline by Kancera AB, H1 2015 201

Colorectal Cancer-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 202

Colorectal Cancer-Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 203

Colorectal Cancer-Pipeline by Laboratorio Elea S.A.C.I.F. and A, H1 2015 204

Colorectal Cancer-Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2015 205

Colorectal Cancer-Pipeline by LivTech, Inc., H1 2015 206

Colorectal Cancer-Pipeline by Lymphocyte Activation Technologies, S.A., H1 2015 207

Colorectal Cancer-Pipeline by Mabion SA, H1 2015 208

Colorectal Cancer-Pipeline by MacroGenics, Inc., H1 2015 209

Colorectal Cancer-Pipeline by MedImmune, LLC, H1 2015 210

Colorectal Cancer-Pipeline by Merck & Co., Inc., H1 2015 211

Colorectal Cancer-Pipeline by Merck KGaA, H1 2015 212

Colorectal Cancer-Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 213

Colorectal Cancer-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 214

Colorectal Cancer-Pipeline by Mirna Therapeutics, Inc., H1 2015 215

Colorectal Cancer-Pipeline by MolMed S.p.A., H1 2015 216

Colorectal Cancer-Pipeline by Mologen AG, H1 2015 217

Colorectal Cancer-Pipeline by Morphotek, Inc., H1 2015 218

Colorectal Cancer-Pipeline by Multimmune GmbH, H1 2015 219

Colorectal Cancer-Pipeline by Natco Pharma Limited, H1 2015 220

Colorectal Cancer-Pipeline by NatureWise Biotech & Medicals Corporation, H1 2015 221

Colorectal Cancer-Pipeline by Nektar Therapeutics, H1 2015 222

Colorectal Cancer-Pipeline by Nerviano Medical Sciences S.r.l., H1 2015 223

Colorectal Cancer-Pipeline by Nippon Kayaku Co., Ltd., H1 2015 224

Colorectal Cancer-Pipeline by Northwest Biotherapeutics, Inc., H1 2015 225

List of Figures

Number of Products under Development for Colorectal Cancer, H1 2015 50

Number of Products under Development for Colorectal Cancer-Comparative Analysis, H1 2015 51

Number of Products under Development by Companies, H1 2015 52

Number of Products under Investigation by Universities/Institutes, H1 2015 68

Comparative Analysis by Late Stage Development, H1 2015 72

Comparative Analysis by Clinical Stage Development, H1 2015 73

Comparative Analysis by Early Stage Products, H1 2015 74

Comparative Analysis by Unknown Stage Development, H1 2015 75

Assessment by Monotherapy Products, H1 2015 279

Assessment by Combination Products, H1 2015 280

Number of Products by Top 10 Targets, H1 2015 281

Number of Products by Stage and Top 10 Targets, H1 2015 281

Number of Products by Top 10 Mechanism of Actions, H1 2015 296

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 296

Number of Products by Top 10 Routes of Administration, H1 2015 308

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 308

Number of Products by Top 10 Molecule Types, H1 2015 310

Number of Products by Stage and Top 10 Molecule Types, H1 2015 310

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

2cureX ApS

3-V Biosciences, Inc.

4SC AG

AB Science

AbbVie Inc.

Actinium Pharmaceuticals, Inc.

Adamed Sp. z o.o.

Advaxis, Inc.

Advenchen Laboratories, LLC

Aeterna Zentaris Inc.

Alchemia Limited

Allinky Biopharma

Amgen Inc.

Angiogene Pharmaceuticals Limited

Antibe Therapeutics, Inc.

Aphios Corporation

Arisaph Pharmaceuticals, Inc.

ArQule, Inc.

Array BioPharma Inc.

Astellas Pharma Inc.

Astex Pharmaceuticals, Inc.

AstraZeneca Plc

AVEO Pharmaceuticals, Inc.

Basilea Pharmaceutica AG

Bavarian Nordic A/S

Bayer AG

Beta Cat Pharmaceuticals, LLC

Biocon Limited

Bionomics Limited

BioNovion B.V.

Biothera, Inc.

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

Burzynski Research Institute, Inc.

cCAM Biotherapeutics Ltd.

CCRP Therapeutics GmbH

Celator Pharmaceuticals, Inc.

Celgene Corporation

Celldex Therapeutics, Inc.

Cellectar Biosciences, Inc.

Cellectis S.A.

Celltrion, Inc.

Cellular Biomedicine Group, Inc.

Celon Pharma Sp. z o.o.

Celsion Corporation

Chipscreen Biosciences Ltd

Chugai Pharmaceutical Co., Ltd.

Cornerstone Pharmaceuticals, Inc.

Critical Outcome Technologies Inc.

CritiTech, Inc.

CrystalGenomics, Inc.

CTI BioPharma Corp.

CureTech Ltd.

Cytune Pharma SAS

Daiichi Sankyo Company, Limited

DanDrit Biotech A/S

Deciphera Pharmaceuticals, LLC

Dicerna Pharmaceuticals, Inc.

Digna Biotech, S.L.

Eddingpharm

Eisai Co., Ltd.

Eli Lilly and Company

EntreChem, S.L.

Enzo Biochem, Inc.

Epirus Biopharmaceuticals, Inc.

Etubics Corporation

Exelixis, Inc.

F. Hoffmann-La Roche Ltd.

Fusion Antibodies Limited

Genentech, Inc.

Genor BioPharma Co., Ltd.

Gilead Sciences, Inc.

GlaxoSmithKline Plc

Glycotope GmbH

Golden Biotechnology Corp.

Gradalis Inc.

Green Cross Corporation

Hanmi Pharmaceuticals, Co. Ltd.

Helix BioPharma Corp.

Hemispherx Biopharma, Inc.

Hospira, Inc.

Hutchison MediPharma Limited

iDD biotech SAS

Ignyta, Inc.

immatics biotechnologies GmbH

Immodulon Therapeutics Ltd.

ImmuneXcite, Inc.

ImmunNovative Developments SL

Immunomedics, Inc.

Immunovative Therapies, Ltd.

Inbiopro Solutions Pvt. Ltd.

Incuron, LLC

Incyte Corporation

Innovent Biologics, Inc.

Interprotein Corporation

Isis Pharmaceuticals, Inc.

Isofol Medical AB

ISU ABXIS Co.,Ltd.

Jiangsu Hengrui Medicine Co., Ltd.

Kadmon Corporation, LLC

Kancera AB

Karyopharm Therapeutics, Inc.

Kyowa Hakko Kirin Co., Ltd.

Laboratorio Elea S.A.C.I.F. and A

Lee's Pharmaceutical Holdings Limited

LivTech, Inc.

Lymphocyte Activation Technologies, S.A.

Mabion SA

MacroGenics, Inc.

MedImmune, LLC

Merck & Co., Inc.

Merck KGaA

Merrimack Pharmaceuticals, Inc.

Millennium Pharmaceuticals, Inc.

Mirna Therapeutics, Inc.

MolMed S.p.A.

Mologen AG

Morphotek, Inc.

Multimmune GmbH

Natco Pharma Limited

NatureWise Biotech & Medicals Corporation

Nektar Therapeutics

Nerviano Medical Sciences S.r.l.

Nippon Kayaku Co., Ltd.

Northwest Biotherapeutics, Inc.

Novartis AG

NuCana BioMed Limited

Oncobiologics, Inc.

Oncology Research International Limited

Oncolytics Biotech Inc.

Onconova Therapeutics, Inc.

Oncothyreon Inc.

Otsuka Holdings Co., Ltd.

Oxford BioMedica Plc

Panacea Biotec Limited

Pfizer Inc.

Pharma Mar, S.A.

Pharmacyclics, Inc.

Philogen S.p.A.

Pivotal BioSciences, Inc.

Plexxikon Inc.

PLx Pharma Inc.

Precision Biologics, Inc.

PsiOxus Therapeutics Limited

Puma Biotechnology, Inc.

Quimatryx, S.L.

Redx Pharma Plc

Regeneron Pharmaceuticals, Inc.

Rexahn Pharmaceuticals, Inc.

Sanofi

Selvita SA

Serina Therapeutics, Inc.

Shanghai Henlius Biotech Co., Ltd.

Sigmoid Pharma Limited

Simcere Pharmaceutical Group

Solvotrin Therapeutics Limited

Sumitomo Dainippon Pharma Co., Ltd.

Sunesis Pharmaceuticals, Inc.

Symphogen A/S

Syndax Pharmaceuticals, Inc.

Tactic Pharma, LLC

Taiho Pharmaceutical Co., Ltd.

Targovax AS

TetraLogic Pharmaceuticals

Teva Pharmaceutical Industries Limited

Theravectys S.A.

TheRyte Limited

TRACON Pharmaceuticals, Inc.

Transgene SA

Vaccinex, Inc.

VasGene Therapeutics, Inc.

Vaxeal Holding SA

Viralytics Ltd.

Wilex AG

WntResearch AB

XBiotech USA, Inc.

Zymeworks Inc.

Zyngenia, Inc.

Colorectal Cancer Therapeutic Products under Development, Key Players in Colorectal Cancer Therapeutics, Colorectal Cancer Pipeline Overview, Colorectal Cancer Pipeline, Colorectal Cancer Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com